Zoetis Inc Reports First Quarter 2025 Results
Zoetis Inc, a leading manufacturer of animal health medicines and vaccines, has released its first quarter 2025 financial results. The company reported revenue and earnings that exceeded market expectations.
Key Highlights
- Revenue growth for the first quarter 2025 exceeded market expectations
- Stock price has declined despite surpassing market expectations
- Revenue growth guidance for 2025 remains unchanged at a range of 6-8%
- Updated 2025 outlook includes the impact of tariffs
Updated Guidance and Outlook
- Revenue growth guidance for 2025 remains at a range of 6-8%
- Updated 2025 outlook includes the impact of tariffs on revenue growth
Analyst Reaction
- Analysts have adjusted their price targets for Zoetis
- Some analysts maintain an “Outperform” rating for the company
Long-Term Prospects
- Zoetis’ stock price has been volatile
- Long-term prospects remain positive due to the company’s strong market position and continued growth in key franchises